Compare DG & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DG | ZTS |
|---|---|---|
| Founded | 1939 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5B | 29.0B |
| IPO Year | 2008 | 2012 |
| Metric | DG | ZTS |
|---|---|---|
| Price | $118.47 | $69.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 30 | 17 |
| Target Price | ★ $140.76 | $96.00 |
| AVG Volume (30 Days) | 1.6M | ★ 3.0M |
| Earning Date | 08-27-2026 | 11-05-2026 |
| Dividend Yield | 1.97% | ★ 3.04% |
| EPS Growth | ★ 34.05 | 10.05 |
| EPS | ★ 4.49 | 3.08 |
| Revenue | ★ $42,724,369,000.00 | $9,467,000,000.00 |
| Revenue This Year | $4.27 | N/A |
| Revenue Next Year | $4.04 | $2.53 |
| P/E Ratio | $27.19 | ★ $22.82 |
| Revenue Growth | ★ 5.20 | 2.28 |
| 52 Week Low | $95.11 | $69.52 |
| 52 Week High | $158.23 | $148.79 |
| Indicator | DG | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 42.56 | 37.74 |
| Support Level | $115.31 | N/A |
| Resistance Level | $120.07 | $78.20 |
| Average True Range (ATR) | 3.39 | 1.58 |
| MACD | -0.54 | -0.20 |
| Stochastic Oscillator | 8.31 | 10.42 |
Since its beginning in 1939, Dollar General has grown to become the largest dollar store operator in the United States, with more than 20,000 small-box discount stores across 48 states. The firm generated over $42 billion in fiscal 2025 sales. The retailer maintains a heavy concentration of stores in rural and low-income markets underserved by big-box retailers. It's 11,000 stock-keeping units, including 2,000 priced at $1 or less, span consumables (82% of sales), seasonal items (10%), home products (5%), and apparel (3%). More than 20% of sales are derived from private label.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.